127 related articles for article (PubMed ID: 8983911)
21. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
22. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
Paridaens R
Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
[TBL] [Abstract][Full Text] [Related]
23. [Docetaxel hydrate for treatment of advanced breast cancers].
Fujii H
Nihon Rinsho; 2000 Apr; 58 Suppl():254-8. PubMed ID: 11026003
[No Abstract] [Full Text] [Related]
24. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer (metastatic).
Stebbing J; Crane J; Gaya A
Clin Evid; 2006 Jun; (15):2331-59. PubMed ID: 16973089
[No Abstract] [Full Text] [Related]
26. The development of docetaxel (Taxotere) in non-small cell lung cancer.
Kris MG; Miller VA; Ng KK; Grant SC
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
[No Abstract] [Full Text] [Related]
27. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
28. [Advances and perspective in clinical research on breast cancer].
Xu BH
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):881-3. PubMed ID: 18478923
[No Abstract] [Full Text] [Related]
29. NICE recommends new treatment for breast and bowel cancer.
Mayor S
BMJ; 2003 May; 326(7400):1166. PubMed ID: 12775610
[No Abstract] [Full Text] [Related]
30. Taxotere shows significant antitumor activity in anthracycline-resistant breast cancer patients.
Oncology (Williston Park); 1994 Sep; 8(9):112. PubMed ID: 7993720
[No Abstract] [Full Text] [Related]
31. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.
Davis AL; Klitus M; Mintzer DM
Clin Breast Cancer; 2005 Dec; 6(5):421-4. PubMed ID: 16381625
[TBL] [Abstract][Full Text] [Related]
32. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
[TBL] [Abstract][Full Text] [Related]
33. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
35. [2nd European Breast Cancer Conference, Bruxelles, September 26-30, 2000. Interview with Anthony Howell].
Howell A
Tumori; 2000; 86(6):A1-4. PubMed ID: 11271673
[No Abstract] [Full Text] [Related]
36. Introduction: taxoids and the management of breast cancer.
Hortobagyi GN
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-1-S13-2. PubMed ID: 9335510
[No Abstract] [Full Text] [Related]
37. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
38. [News in the medical treatment of breast cancer].
Piccart M; Dochy E; Cardoso F
Bull Cancer; 2003 Jan; 90(1):46-52. PubMed ID: 12609804
[TBL] [Abstract][Full Text] [Related]
39. The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.
Ryan PD; Goss PE
Nat Clin Pract Oncol; 2005 Dec; 2(12):596-7. PubMed ID: 16341095
[No Abstract] [Full Text] [Related]
40. Paclitaxel and docetaxel. Innovation, but at what cost?
Lønning PE
Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
